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A B S T R A C TObjectives: Early estimates of the commercial headroom available to a
new medical device can assist producers of health technology in
making appropriate product investment decisions. The purpose of this
study was to illustrate how this quantity can be captured probabilisti-
cally by combining probability elicitation with early health economic
modeling. The technology considered was a novel point-of-care testing
device in heart failure disease management. Methods: First, we devel-
oped a continuous-time Markov model to represent the patients’
disease progression under the current care setting. Next, we identified
the model parameters that are likely to change after the introduction of
the new device and interviewed three cardiologists to capture the
probability distributions of these parameters. Finally, we obtained the
probability distribution of the commercial headroom available per
measurement by propagating the uncertainty in the model inputs to
uncertainty in modeled outcomes. Results: For a willingness-to-pay
value of h10,000 per life-year, the median headroom available persee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.02.008
cg.nl.
ndence to: Qi Cao, Department of Epidemiology, U
Groningen, The Netherlands.measurement was h1.64 (interquartile range h0.05–h3.16) when the
measurement frequency was assumed to be daily. In the subsequently
conducted sensitivity analysis, this median value increased to a
maximum of h57.70 for different combinations of the willingness-to-
pay threshold and the measurement frequency. Conclusions: Proba-
bility elicitation can successfully be combined with early health
economic modeling to obtain the probability distribution of the head-
room available to a new medical technology. Subsequently feeding this
distribution into a product investment evaluation method enables
stakeholders to make more informed decisions regarding to which
markets a currently available product prototype should be targeted.
Keywords: early health economic modeling, headroom analysis, heart
failure disease management, probability elicitation.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Investment in the research and development of new medical
technology typically results in several promising product con-
cepts. There is usually, however, insufficient funding to further
develop each of these concepts into concrete products that can be
brought to the market. This forces producers of medical technol-
ogy and other stakeholders, such as venture capitalists and
funding agencies, to already decide early during the product
development process which of these concepts to abandon and
which of them to push forward for further development [1–5].
In the current practice of product investment decision mak-
ing, such decisions often seem to be based on potentially
arbitrary representations of the expected improvements in out-
comes and costs resulting from the use of the new technology. A
factual representation of the current care situation and the
specific changes that are likely to occur after the new technology
has been fully adopted is generally not elaborated. Thus, deci-
sions regarding the selection of suitable target markets for a
currently available prototype technology are reached in asimilarly arbitrary way. Early-stage health economic modeling
has recently been suggested as a tool for supporting product
investment decision making in a more formal way as it can
provide insight into the maximum additional cost at which the
intended clinical use of the new technology in a selected target
market is still deemed cost-effective [3]. This upper bound on the
technology’s maximum cost, also known as the commercial
headroom available [4,6], can then be fed into an appropriate
product investment evaluation method to determine whether
further development of the prototype technology is likely to yield
sufficient return on investment [7,8].
In early-stage health economic evaluations, there is usually
only a limited amount of data available with regard to the
performance of the new technology, leading to high uncertainty
in the values of some of the model inputs [9]. Expert judgment
therefore needs to be relied on to obtain initial estimates of those
parameters for which sufficient clinical evidence is not yet
available. Probability elicitation (PE) refers to a set of techniques
for formulating one or more experts’ beliefs about the unknown
parameters into a probability distribution of those parametersSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – Schematic representation of the approach used in this article.
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handle parameter uncertainty in health economic models [12–14].
In this article, we take the use of this approach one step further by
illustrating how PE can be combined with early health economic
modeling to obtain the probability distribution of the commercial
headroom available to a novel point-of-care testing (POCT) device,
which is defined as laboratory testing at or near the patient, in the
disease management of patients with heart failure (HF).12qMethods
The approach that we used for combining PE with early health
economic modeling is summarized in Figure 1. First, conceptual
models of the current care setting (e.g., the health care setting in
which the conventional disease management strategies are
applied) and the new care setting (e.g., the health care setting
in which the novel POCT device is introduced) were developed.
Then, a continuous-time Markov model that appropriately
reflects the disease progression in patients under the current
care setting was developed. Next, the model parameters that are
likely to change under the new care setting were identified. These
served as the unknown Parameter(s) of Interest (uPoI) for which
PE was subsequently conducted. Finally, the commercial head-
room available was calculated and its uncertainty was captured
probabilistically by propagating the uPoI distributions.
Conceptual Models of the Two Health Care Settings
The current care comparator depends on the clinical setting in
which the POCT device will be applied after it has been brought to
the market. As this device could potentially be used in different
clinical settings (e.g., outpatient clinic, home setting), we used semi-
structured interviews to learn from the clinical experts in which
setting the introduction of the POCT device was likely to generate
the highest clinical impact. As none of the cardiologists could see
any value in the use of this device in the outpatient setting, we
decided to focus the early health economic assessment around the
introduction of the POCT device in the home setting. More detailed
assumptions on how the device would affect the care pathway
when introduced in this setting were subsequently elicited from the
same experts. Based on the results of these interviews, the current
and new care settings were defined as follows:Discharged Hospital readmission 
alive (state 1) (state 2) 
21q
13q 23qThe current care setting consisted of several follow-up visits
to the cardiologist and of additional support provided by
nurses with special education and training in HF manage-
ment. During the first 4 months after discharge, patients on
average have one visit to the cardiologist and four visits to one
of the HF nurses. After this initial period, the number of
outpatient visits reduces to a yearly follow-up visit to the
cardiologist. After an HF-related readmission, the above visit-
ing frequency was repeated. Death (state 3) 
Fig. 2 – Structure of the continuous-time Markov model.The new care setting consisted of the introduction of the
novel POCT device in the home setting to allow for more
efficient monitoring of an HF patient’s disease progression.
The home measuring itself was not expected to change the
outpatient visiting frequency.Markov Model
To estimate the expected health outcomes and costs under the
current care setting, we developed a continuous-time Markov
model with three health states (Fig. 2): discharged alive from
hospital, HF-related hospital readmission, and death. For prac-
tical purposes, the transition intensities were assumed to be
constant over time and independent of patient-related risk
factors. We used the data collected during the Coordinating
Study Evaluating Outcomes of Advising and Counseling in Heart
Failure (COACH), one of the largest multicenter, randomized
controlled trials of nurse-led disease management programs in
HF [15,16], to estimate the current care model parameters. To be
consistent with our description of the current care setting, we
included all patients from COACH who received additional basic
or intensive support from a nurse specialized in the disease
management of patients with HF. This resulted in a total sample
size of 684. To make the model of the current care setting
probabilistic, simple random sampling with replacement was
conducted to obtain 10,000 resamples of equal size to the original
sample. For each bootstrap resample, the current care transition
intensities were subsequently estimated by using the msm pack-
age for R [17], resulting in 10,000 realizations from the joint
probability distribution of the current care transition intensities.
Unit costs for outpatient visits and HF-related hospitalization
were taken from Postmus et al. [18] and set to be equal to h110/
visit and h769/d, respectively.Probability Elicitation of the Unknown Model Parameters
The transition intensities of the continuous-time Markov model
were identified as the uPoI for the new care setting. The same
three cardiologists who assisted in developing the conceptual
models of the two health care settings were invited to take part in
the face-to-face PE interviews. We took the suggestions from
Soares et al. [13] and expressed the uPoI in terms of more directly
observable quantities for which the experts’ beliefs were elicited.
In particular, let Ti denote the amount of time spent in health
state i, let FiðtiÞ denote the proportion of patients who have left
health state i by time ti, and let Pij denote the probability that
Table 1 – Mean values (95% confidence intervals) of
the transition intensities under the current care
setting
q.1 q.2 q.3
q1. 0.00078
(0.00069, 0.00089)
0.00043
(0.00036, 0.00051)
q2. 0.06810
(0.05940, 0.07789)
0.01070
(0.00769, 0.01517)
q3. 0 0
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 2 9 – 5 3 5 531when leaving state i the next state will be state j. For a
continuous-time Markov model, it holds that Ti is exponentially
distributed with mean value 1=
P
iajqij, where qij denotes the
transition intensity between health states i and j [17,19]. This
allows us to express FiðtiÞ as follows:
FiðtiÞ¼1expð
X
iaj
qijtiÞ ði¼1, 2; j¼1, 2, 3Þ ð1Þ
Similarly, the transition probabilities Pij can be expressed in
terms of the transition intensities as follows:
Pij¼
qijP
iajqij
ði¼1, 2; j¼1, 2, 3Þ ð2Þ
By combining Equations 1 and 2, the transition intensities qij
can be expressed as follows:
qij¼
pij logð1FiðtiÞÞ
ti
ði¼1, 2; j¼1, 2, 3; iajÞ ð3Þ
To obtain the probability distributions of qij, we elicited point
estimates of the transition probabilities pij and used the fixed
interval elicitation method [10,11] to capture the probability
distributions of FiðtiÞ ði¼1, 2Þ at the time points t1¼365 days and
t2¼10 days. Equation 3 was then used to capture the qij distribu-
tions from the elicited FiðtiÞ ði¼1, 2Þ distributions and pij values. A
detailed description of the method of data capture and the
distribution fitting is provided in Supplementary Material I found
at http://dx.doi.org/10.1016/j.jval.2013.02.008.
Analysis of the Commercial Headroom Available
Let e0 and c0 be the expected survival time and cost derived from
the current care model, and let e1 and c1r be the expected survival
time and non–device-related cost derived from the new care
model. The expected overall commercial headroom available to
the new device can then be computed as follows:
h¼lDeDc ð4Þ
where l denotes the willingness-to-pay per life-year, and
Dc¼c1rc0 and De¼e1e0 denote the expected incremental
non–device-related cost and the expected improvement in sur-
vival time due to the use of the new technology (also known as
the effectiveness gap [20]), respectively.
The POCT of circulating cardiac biomarkers involves placing a
disposable containing a patient’s blood sample in an analyzer
that is located at or near the patient. Denoting the cost of the
analyzer by c1ana and the cost of a disposable by c1dis, the total
device-related cost can be expressed as follows:
c1d¼c1anaþc1distmfm ð5Þ
where tm and fm are the expected out-of-hospital days and the
out-of-hospital measurement frequency (expressed in number of
measurements per day), respectively. Assuming that the fully
developed product will be applied in daily clinical practice only if
its use is considered to be cost-effective, the commercial head-
room available reflects the maximum price at which the POCT
device can be sold on the market. Further development of the
device into a tool for monitoring HF disease progression may
therefore not be viable if the total device-related cost is likely to
exceed this value. Equating 4 and 5 and dividing by the total
number of measurements, this upper bound on the device-
related cost can formally be expressed as follows:
c1disþ
c1ana
tmfm
r lDeDc
tmfm
ð6Þ
where the left-hand side denotes the average cost per measure-
ment and the right-hand side the commercial headroom avail-
able per measurementPer expert, the uncertainty in the amount of headroom
available per measurement was captured in a probabilistic way
by propagating the uncertainty in the uPoI. This was achieved by
repeatedly (10,000 times) sampling the current care transition
intensities and the uPoI values from their corresponding proba-
bility distributions to obtain different values ofDe, Dc, and tm and
then computing ðlDeDcÞ=tmfm for given values of l and fm. For a
given realization of the current care transition intensities and the
uPoI, Dc was estimated by taking the difference in the expected
values of c1r and c0 and De was estimated by taking the difference
in the expected values of e1 and e0. The expected values of c0, e0,
c1r, e1, and tm were obtained by taking the mean values of 10,000
first-order Monte Carlo simulation runs [21] from the two
continuous-time Markov models, using a 5-year time horizon.
This relatively short time period was selected to ensure that the
assumption of constant transition intensities for the continuous-
time Markov model would still be reasonable. As up to 70% of all
patients with HF die within 5 years of their first hospital
admission [22], this period should still be long enough to capture
most of the health effects resulting from introducing the novel
POCT device in this patient population. To combine multiple
experts’ opinions into a single distribution of the commercial
headroom available per measurement, we performed linear
opinion pooling with equal experts’ weighting [10,11].Results
Current Care Model
After 18 months of follow-up in COACH, 270 (39%) patients reached
the combined end point of HF hospitalization and death. Out of
these patients, 176 (65%) had been readmitted to the hospital and
94 (35%) had died. In total, 242 HF hospitalizations were recorded
in the study cohort. The mean duration of hospital stay was 13
days, and the incidence of in-hospital mortality was 14%.
The estimated values of the transition intensities under the
current care setting are provided in Table 1. Using Equation 2, the
corresponding incidences of out-of-hospital and in-hospital mor-
tality were 36% and 13%, respectively. The estimated mean
hospital stay in the Markov model was 13 days. The event rates
and mean hospital duration as predicted from the Markov model
are close to the event rates and mean hospital duration as
observed in COACH, showing that the current care model fitted
the observed data well.
Probability Elicitation
One cardiologist was unable to complete the PE interview
because he found that it was impossible to provide any reliable
quantitative judgments with regard to this new device applica-
tion. The probability distributions of FiðtiÞ in state i¼1 (t1¼ 365
days) and state i¼2 (t2¼ 10 days) and the values of pij that were
elicited from the two remaining cardiologists are provided in
Supplementary Material II found at http://dx.doi.org/10.1016/j.
Fig. 3 – Comparison of the probability distributions of the current care transition intensities as obtained using bootstrapping
and the probability distributions of the new care transition intensities as elicited from the two experts.
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together with the corresponding probability distributions of these
parameters under the current care setting are depicted in
Figure 3. Both experts believed that the introduction of the POCT
device would not have a profound impact on the number of
transitions from the discharged alive to the death state, but they
had different opinions on how the use of this device would affect
the number of hospital readmissions. The first expert believed
that individually tailored drug doses in response to the observed
biomarker trajectories would result in fewer hospital readmis
sions, while the second expert believed that the repeated bio
marker measurements would increase admission rates among
patients with less severe clinical signs and symptoms. This
explains why, compared with the current care setting, the mode
of the distribution of q12 is shifted to the left for expert 1 and to
the right for expert 2. The first expert also believed that the
introduction of the POCT device would not affect the transition
intensities out of the hospital readmission state. For this expert,
we therefore assumed that the probability distributions of the
transition intensities out of the hospital readmission state underthe new care setting were equal to the probability distributions of
these intensities under the current care setting. The second
expert, in contrast, believed that because of the increased
admission rates among patients with less severe clinical signs
and symptoms, the average length of stay in the hospital would
decrease and the proportion of patients discharged alive would
increase. This explains why, compared with the current
care setting, the mode of the distribution of q21 is shifted to the
right while the mode of the distribution of q23 is shifted to
the left.
Headroom Analysis
Figure 4 summarizes the distributions of the commercial head-
room available per measurement based on separate and pooled
experts’ opinions for the base-case scenario of a willingness-to-
pay threshold of h10,000 per life-year and a daily measurement
frequency as suggested by one of the cardiologists. The corre-
sponding pooled lower quartile, median, and upper quartile
were h0.05, h1.64, and h3.16 per measurement, respectively.
Fig. 4 – Probability distribution of the commercial headroom
available per measurement for k ¼ h10,000 per life-year and
fm ¼ 1.
Fig. 5 – Median commercial headroom available per
measurement against k for different values of the
measurement frequency.
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the willingness-to-pay threshold and the measurement fre-
quency is depicted in Figure 5. In comparison to the base-case
value of h1.64, the median commercial headroom available per
measurement increased to h11.48 when the measurement
frequency was decreased to weekly and increased to h8.24
when the willingness-to-pay threshold was increased to
h80,000 per life-year. When both these parameters were simul-
taneously set to their most favorable values, the commercial
headroom available per measurement further increased to
h57.70.Discussion
Early-stage health economic evaluations are characterized by
evidence scarcity because data from clinical research are usually
still missing. This lack of clinical evidence leads to high uncer-
tainty in some of the model inputs, which can generally be
resolved only by incorporating expert opinion. In this article,
experts’ beliefs were first elicited through semi-structured inter-
views to develop appropriate conceptual models of the health
care settings without and with the use of a new medical
technology. PE was then applied to quantitatively capture
experts’ beliefs in a probabilistic way to handle parameter
uncertainty in the subsequently constructed mathematical mod-
els. Finally, Monte Carlo simulation was applied to propagate the
uncertainty in the model inputs to uncertainty in the modeled
outcomes and to obtain a probability distribution of the amount
of headroom available per measurement.
Technology-driven innovation consists of several phases,
ranging from idea generation and application selection to the
commercialization and launching of the developed products [23].
Given the specific characteristics of such projects, the use of
early-stage health economic evaluation as a tool for informing
product investment decision making seems especially useful at
the intersection between ‘‘investigation and technology transfer’’
and ‘‘development and validation,’’ where it has to be decided to
which markets the currently available prototype technology isbeing targeted, if any. For the case study considered in this
article, the prototype technology was a novel POCT device for
measuring one or more circulating biomarkers, and the market
considered was the disease management of patients with HF. For
this application of the prototype technology, the median (inter-
quartile range) of the commercial headroom available per meas-
urement was found to be equal to h1.64 (h0.05–h3.16) for a
willingness-to-pay threshold of h10,000 per life-year and a daily
measurement frequency. Further development of the device into
a tool for monitoring HF disease progression may therefore not be
viable if the average cost per measurement is expected to be
much larger than these values, which can be assessed more
formally by feeding the obtained distribution of the commercial
headroom available into the product investment evaluation
method proposed by Girling et al. [7]. This involves comparing
the projected postmarket cash flows resulting from selling the
analyzer and the disposable at a price that puts the average cost
per measurement just below the commercial headroom available
per measurement to the expected development cost to determine
whether further development of the prototype technology into a
commercial product for HF disease management is likely to yield
sufficient return on investment.
An important prerequisite of the use of elicitation in early
health economic modeling is that experts need to be able or
willing to provide values for the unknown model parameters. The
method can therefore not be applied when experts do not want to
speculate about the clinical impact of a not yet fully developed
product. This problem was also encountered in our case study
and led to the dropout of one of the cardiologists from partic-
ipating in the elicitation exercise. Attempts to support product
investment decision making through early health economic
modeling may therefore not be successful when the impact of
introducing the new technology in a selected clinical setting is
difficult to perceive by the participating experts. Also, at the start
of the product development process, there are typically many
technological solution principles and/or target markets left to
choose from, giving rise to a large variety of potential products.
Other, more qualitative approaches are then required to perform
an initial screening of the generated product concepts.
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expert beliefs were mostly incorporated by eliciting point esti-
mates of the uPoI as well as their minimum and maximum
values to facilitate a subsequent sensitivity analysis [24–27].
Although this so-called deterministic value elicitation approach
is easier to use than the PE approach applied in this article, it
does not allow the parameter uncertainty to be explicitly repre-
sented and assessed regarding its impact. Propagating the uncer-
tainty in the model inputs to uncertainty in the modeled
outcomes is nevertheless essential if one wants to support
product investment decision making through the use of formal
decision support methods, such as the one described previously.
A downside of using PE is that attaching likelihoods to the values
of unknown parameters is not straightforward. Care must there-
fore be taken to parameterize the uPoI in terms of quantities that
still have a clear interpretation. For the Markov model considered
in this article, the transitions out of the two transient health
states are subjected to competing risks, meaning that the overall
effect of the POCT device on the number of transitions from state
i to state j depends not only on the effect of this device on qij but
also on its effect on the other transition intensity out of state i
[28]. We therefore decided not to use hazard ratios to parameter-
ize the transition intensities of the new care model in terms of
the transition intensities of the current care model. Instead, we
followed the approach taken by Soares et al. [13] and para-
meterized the transition intensities of the new care model in
terms of two directly observable quantities and elicited their
absolute values and their uncertainty conditional on the mean
values of these quantities under the current care setting. The
mean values of these quantities under the current setting there-
fore served as reference values based on which the experts’
opinions were elicited. As the elicitation exercise was not
repeated for different reference values, the underlying assump-
tion of our approach is that an expert’s opinion on the new care
transition intensities does not depend on the specific values of
these intensities under the current care setting. Our approach
may therefore not be valid when experts believe that there is a
large correlation between the current care and the new care
transition intensities.
In specifying the Markov model, we assumed that the tran-
sition intensities were homogeneous (e.g., independent of
time) and constant across patients. One way to relax these
assumptions would be to include time and patient characteristics
as regressors within the same model structure [29]. This would
also result, however, in many more parameters to elicit and
therefore seems less suitable for early-stage health economic
modeling. In addition, there were only two experts who partici-
pated in the PE interviews. The resulting pooled distribution of
the commercial headroom available may therefore not represent
consensuses among a larger group of experts. A final important
decision that has to be taken when combining PE with early
health economic modeling is when the pooling of the different
experts’ opinions has to be conducted. In our study, the proba-
bility distributions of the uPoI served as intermediate outcomes
that were transformed into a probability distribution of the
commercial headroom available per measurement, the main
outcome of interest. We therefore decided to not directly pool
the distributions of the uPoI but to postpone the pooling until the
uncertainty in the model inputs was propagated to uncertainty in
the modeled outcomes, resulting in both individual and aggre-
gated distributions of the commercial headroom available per
measurement.
To conclude, this study illustrated by means of a case study
how PE can be combined with early health economic modeling to
obtain the probability distribution of the commercial headroom
available to a new medical technology. By subsequently feeding
this distribution in a formal product investment evaluationmethod, the decision to which markets a currently available
prototype technology should be targeted, if any, can be taken in a
more informed way, which should ultimately result in higher
return on investment for all stakeholders.Acknowledgments
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